Importantly, we have developed NDI, a potentially novel antagonist peptide that effectively blocks the Notch1-DLL4 interaction, reducing endothelial PANoptosis, systemic inflammation, ALI, and mortality in sepsis (Figure 7). Here, DLL4 is linked to Sepsis.